O	0	3	The
O	4	10	effect
O	11	13	of
B-intervention	14	20	fibrin
I-intervention	21	28	sealant
I-intervention	29	37	combined
I-intervention	38	42	with
I-intervention	43	55	fibrinolysis
I-intervention	56	65	inhibitor
O	66	68	on
O	69	77	reducing
O	78	81	the
B-condition	82	88	amount
I-condition	89	91	of
I-condition	92	101	lymphatic
I-condition	102	109	leakage
I-condition	110	115	after
I-condition	116	124	axillary
I-condition	125	135	evacuation
O	136	138	in
O	139	145	breast
O	146	152	cancer
O	152	153	.

O	154	155	A
O	156	167	prospective
O	168	178	randomized
O	179	187	clinical
O	188	193	trial
O	193	194	.

O	195	198	One
O	199	204	third
O	205	207	of
O	208	213	women
O	214	224	undergoing
O	225	235	mastectomy
O	236	240	with
O	241	249	axillary
O	250	260	evacuation
O	261	264	for
O	265	272	primary
O	273	279	breast
O	280	286	cancer
O	287	293	suffer
O	294	298	from
O	299	312	postoperative
O	313	320	seromas
O	321	328	leading
O	329	331	to
O	332	343	unnecessary
O	344	349	costs
O	350	353	and
O	354	367	complications
O	368	372	such
O	373	375	as
O	376	386	infections
O	387	390	and
O	391	394	new
O	395	405	operations
O	405	406	.

O	407	416	Different
O	417	424	methods
O	425	427	to
O	428	435	prevent
O	436	442	seroma
O	443	452	formation
O	453	457	have
O	458	462	been
O	463	468	tried
O	469	476	without
O	477	486	permanent
O	487	494	success
O	494	495	.

O	496	499	The
O	500	503	aim
O	504	506	of
O	507	511	this
O	512	523	prospective
O	524	534	randomised
O	535	540	study
O	541	544	was
O	545	547	to
O	548	555	examine
O	556	559	the
O	560	566	effect
O	567	569	of
O	570	576	fibrin
O	577	584	sealant
O	585	589	with
O	590	602	fibrinolysis
O	603	612	inhibitor
O	613	620	firstly
O	621	623	on
O	624	627	the
O	628	637	reduction
O	638	640	of
O	641	644	the
O	645	651	amount
O	652	654	of
O	655	664	lymphatic
O	665	672	leakage
O	673	678	after
O	679	687	axillary
O	688	698	evacuation
O	699	702	and
O	703	711	secondly
O	712	714	on
O	715	718	the
O	719	728	reduction
O	729	731	of
O	732	736	days
O	737	741	with
O	742	748	drains
O	749	752	and
O	753	766	postoperative
O	767	773	seroma
O	774	783	punctures
O	783	784	.

B-total-participants	785	787	40
B-eligibility	788	796	patients
I-eligibility	797	801	with
I-eligibility	802	809	primary
I-eligibility	810	816	breast
I-eligibility	817	823	cancer
O	824	828	were
O	829	842	prospectively
O	843	853	randomised
O	854	856	to
O	857	860	the
O	861	870	treatment
O	871	876	group
O	877	878	(
O	878	879	n
O	880	881	=
B-intervention-participants	882	884	19
O	884	885	)
O	886	893	getting
O	894	900	fibrin
O	901	905	glue
O	906	914	combined
O	915	919	with
O	920	932	fibrinolysis
O	933	942	inhibitor
O	943	944	(
O	944	953	aprotinin
O	953	954	)
O	955	962	sprayed
O	963	967	into
O	968	971	the
O	972	980	axillary
O	981	986	fossa
O	987	990	and
O	991	993	to
O	994	997	the
B-control	998	1005	control
I-control	1006	1011	group
O	1012	1013	(
O	1013	1014	n
O	1015	1016	=
B-control-participants	1017	1019	21
O	1019	1020	)
O	1020	1021	.

O	1022	1027	There
O	1028	1032	were
O	1033	1035	no
O	1036	1047	differences
O	1048	1050	in
O	1051	1054	the
B-outcome	1055	1064	incidence
I-outcome	1065	1067	of
I-outcome	1068	1081	postoperative
I-outcome	1082	1089	seromas
O	1090	1097	between
O	1098	1101	the
O	1102	1108	groups
O	1108	1109	.

O	1110	1117	However
O	1117	1118	,
O	1119	1122	the
O	1123	1130	seromas
O	1131	1135	were
O	1136	1142	easier
O	1143	1145	to
O	1146	1151	treat
O	1152	1154	if
O	1155	1161	fibrin
O	1162	1166	clue
O	1167	1170	was
O	1171	1175	used
O	1175	1176	.

O	1177	1182	Total
O	1183	1191	quantity
O	1192	1193	(
O	1193	1197	mean
O	1197	1198	+
O	1198	1199	/
O	1199	1200	-
O	1200	1202	SD
O	1202	1203	)
O	1204	1206	of
B-outcome	1207	1218	lymphorrhea
I-outcome	1219	1222	and
I-outcome	1223	1228	total
I-outcome	1229	1235	number
I-outcome	1236	1238	of
I-outcome	1239	1250	aspirations
O	1251	1252	(
O	1252	1256	mean
O	1256	1257	+
O	1257	1258	/
O	1258	1259	-
O	1259	1261	SD
O	1261	1262	)
O	1263	1267	were
O	1268	1274	almost
O	1275	1280	twice
O	1281	1283	as
O	1284	1288	high
O	1289	1291	in
O	1292	1295	the
O	1296	1304	patients
O	1305	1307	of
O	1308	1311	the
O	1312	1319	control
O	1320	1325	group
O	1326	1334	compared
O	1335	1337	to
O	1338	1343	those
O	1344	1350	having
O	1351	1357	fibrin
O	1358	1365	sealant
O	1365	1366	.

O	1367	1369	In
O	1370	1373	the
O	1374	1383	treatment
O	1384	1389	group
O	1390	1397	seromas
O	1398	1406	resolved
O	1407	1412	after
O	1413	1416	one
O	1417	1419	or
O	1420	1432	occasionally
O	1433	1438	after
O	1439	1442	two
O	1443	1454	aspirations
O	1455	1457	in
B-iv-bin-percent	1458	1460	71
I-iv-bin-percent	1461	1462	%
O	1463	1465	of
O	1466	1474	patients
O	1474	1475	,
O	1476	1481	while
O	1482	1484	in
O	1485	1488	the
O	1489	1496	control
O	1497	1502	group
B-cv-bin-percent	1503	1505	90
I-cv-bin-percent	1506	1507	%
O	1508	1510	of
O	1511	1519	patients
B-outcome	1520	1526	needed
I-outcome	1527	1532	three
I-outcome	1533	1535	or
I-outcome	1536	1540	more
I-outcome	1541	1552	aspirations
O	1552	1553	.

O	1554	1565	Potentially
O	1565	1566	,
O	1567	1573	fibrin
O	1574	1581	sealant
O	1582	1590	combined
O	1591	1595	with
O	1596	1608	fibrinolysis
O	1609	1618	inhibitor
O	1619	1624	might
O	1625	1627	be
O	1628	1632	used
O	1633	1636	for
O	1637	1640	the
O	1641	1650	treatment
O	1651	1653	of
O	1654	1658	post
O	1658	1659	-
O	1660	1668	axillary
O	1669	1679	evacuation
O	1680	1691	lymphorrhea
O	1692	1695	and
O	1696	1702	seroma
O	1702	1703	.
